Wanbury Limited (WANBURY) Fair Value & Analysis
Healthcare · IN · Market cap ₹10.0B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +11.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹163.34 – ₹308.65 · fair‑value band ₹256.73 – ₹472.68 · the ₹286.45 price screens below the ₹365.74 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Wanbury Limited (WANBURY) currently trades at ₹286.45, while our model-based Fair Value estimate is ₹365.74 — implying the stock looks roughly 27.7% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Wanbury Limited generated revenue of ₹3.7B at a net margin of -25.9%. Revenue declined 19.2% year over year. It earns a return on equity of 68.7%. Net debt stands at ₹2.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Wanbury Limited reported revenue of ₹6.5B in FY2026 versus ₹5.1B in FY2022, a compound +6.2%/yr. Reported net income was ₹661M in FY2026, compounding −5.1%/yr from FY2022.
Is WANBURY fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wanbury Limited (WANBURY) undervalued?
What is the fair value of WANBURY?
What is the quality score of WANBURY?
What is the revenue of Wanbury Limited (WANBURY)?
What is the net profit margin of WANBURY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.